First author [ref.] | Drug | Patients n | Duration weeks | Rescue medication | Dyspnoea | Exercise |
Casaburi [8] | Tiotropium 18 µg | 921 | 52 | ↑ | ↑ | NA |
Brusasco [9] | Tiotropium 18 µg | 1207 | 26 | NA | ↑ | NA |
O'Donnell [6] | Tiotropium 18 µg | 187 | 6 | ↑ | ↑ | ↑ |
Casaburi [10] | Tiotropium 18 µg | 91 | 25 | ↑# | ↑ | ↑ |
Tonnel [12] | Tiotropium 18 µg | 554 | 36 | NA | NA | NA |
Niewoehner [13] | Tiotropium 18 μg | 1829 | 24 | NA | NA | NA |
Maltais [11] | Tiotropium 18 µg | 261 | 6 | ↑ | ↑ | ↑ |
Verkindre [14] | Tiotropium 18 µg | 100 | 12 | NA | NS | ↑ |
Dusser [15] | Tiotropium 18 µg | 1010 | 52 | ↑ | NA | NA |
Boyd [16] | Salmeterol 50 µg | 674 | 16 | ↑ | ↑ | NS |
Jones [17] | Salmeterol 50 µg | 283 | 16 | ↑ | NA | NA |
Mahler [18] | Salmeterol 42 µg | 411 | 12 | ↑ | NS# | NS |
Rutten-van Mölken [19] | Salmeterol 50 µg | 144 | 12 | NA | NA | NA |
van Noord [20] | Salmeterol 50 µg | 144 | 12 | ↑ | NA | NA |
Rennard [21] | Salmeterol 42 µg | 405 | 12 | ↑ | NS | NS |
Chapman [22] | Salmeterol 50 µg | 408 | 24 | NS | NA | NA |
Mahler [23] | Salmeterol 50 µg | 691 | 24 | ↑ | NS | NA |
Brusasco [9] | Salmeterol 50 µg | 1207 | 26 | NA | ↑ | NA |
Calverley [24] | Salmeterol 50 µg | 1465 | 52 | ↑ | NS¶ | NA |
Hanania [25] | Salmeterol 50 µg | 723 | 24 | NA | ↑ | NA |
O'Donnell [26] | Salmeterol 50 µg | 23 | 2 (crossover) | NA | ↑ | ↑ |
Dahl [27] | Formoterol 12 µg or 24 µg | 780 | 12 | ↑ | NA | NA |
Aalbers [28] | Formoterol 12 µg or 24 µg | 687 | 12 | ↑ | NS | NS |
Rossi [29] | Formoterol 12 µg or 24 µg | 854 | 52 | ↑ | NA | NA |
Szafranski [30] | Formoterol 12 µg or 24 µg | 812 | 52 | NM | NM¶ | NA |
↑: significant benefit versus placebo (e.g. reduced dyspnoea, increased exercise tolerance); NA: not assessed; NS: no significant benefit versus placebo; NM: not mentioned. #: significant benefit at weeks 2, 4, 8 and 10; ¶: symptom score breathlessness.